Proactive Research analyst Emma Ulker says US partnering discussions at Shield Therapeutics (LON:STX) are progressing and it's a key factor given that the US represents around 70% of the US$3bn global iron replacement market.
Ulker adds that the balance sheet was recently bolstered by an US$11.4mln milestone payment from China partner ASK Pharm, providing liquidity in the months ahead to negotiate potential uncertainty owing to the coronavirus crisis.
